行情

VXRT

VXRT

VAXART
NASDAQ

实时行情|Nasdaq Last Sale

0.3189
+0.0039
+1.24%
已收盘, 16:00 12/06 EST
开盘
0.3097
昨收
0.3150
最高
0.3297
最低
0.3097
成交量
18.97万
成交额
--
52周最高
5.00
52周最低
0.2543
市值
1,474.07万
市盈率(TTM)
-0.2020
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VXRT 新闻

  • 意大利再次修正2020财政预算案 推多项惠民政策
  • 中国新闻网.3天前
  • 兴业银行:美国国债收益率或将因衰退风险而跌至1.2%
  • 新浪财经综合.3天前
  • 波音737 MAX审查进展:FAA局长将赴众院说明情况
  • 中国新闻网.3天前
  • 美股超级牛派:最近的下跌是早来的圣诞礼物
  • 新浪财经.3天前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
+0.32%

热门股票

名称
价格
涨跌幅

VXRT 简况

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
展开

Webull提供Vaxart Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。